Advanced search
Publication Cover
Postgraduate Medicine Volume 131, 2019 - Issue 3
Submit an article Journal homepage
253
Views
6
CrossRef citations to date
0
Altmetric
Clinical Features - Case Report

Apremilast efficacy and safety in a psoriatic arthritis patient affected by HIV and HBV virus infections

Valeria ManfredaDepartment of Dermatology, University of Rome “Tor Vergata”, Rome, ItalyCorrespondence[email protected]
View further author information
,
Maria EspositoDepartment of Dermatology, University of Rome “Tor Vergata”, Rome, ItalyView further author information
,
Elena CampioneDepartment of Dermatology, University of Rome “Tor Vergata”, Rome, ItalyView further author information
,
Luca BianchiDepartment of Dermatology, University of Rome “Tor Vergata”, Rome, ItalyView further author information
&
Alessandro GiuntaDepartment of Dermatology, University of Rome “Tor Vergata”, Rome, Italy;Dermatology, Department of Clinical Sciences and Translational Medicine, International Medical School, University of Rome “Tor Vergata”, Rome, ItalyView further author information
Pages 239-240 | Received 20 Dec 2018, Accepted 25 Jan 2019, Published online: 08 Feb 2019

References

  • Menon K, Van Voorhees AS, Bebo BF Jr., et al. National Psoriasis Foundation. Psoriasis in patients with HIV infection: from the medical board of the National Psoriasis Foundation. J Am Acad Dermatol. 2010;62(2):291–299.
  • Bardazzi F, Magnano M, Campanati A, et al. Biologic therapies in HIV-infected patients with psoriasis: an Italian experience. Acta Derm Venereol. 2017 Aug 31;97(8):989–990.
  • Bonifati C, Lora V, Graceffa D, et al. Management of psoriasis patients with hepatitis B or hepatitis C virus infection. World J Gastroenterol. 2016;22(28):6444–6455.
  • Torres T, Puig L. Apremilast: a novel oral treatment for psoriasis and psoriatic arthritis. Am J Clin Dermatol. 2018;19(1):23–32.
  • Crowley J, Thaçi D, Joly P, et al. Long-term safety and tolerability of apremilast in patients with psoriasis: pooled safety analysis for ≥156 weeks from 2 phase 3, randomized, controlled trials (ESTEEM 1 and 2). J Am Acad Dermatol. 2017;77(2):310–317.e1.
  • Gooderham M, Papp K. Selective phosphodiesterase inhibitors for psoriasis: focus on apremilast. BioDrugs. 2015;29(5):327–339.
  • Kaushik SB, Lebwohl MG. Psoriasis: which therapy for which patient: focus on special populations and chronic infections. J Am Acad Dermatol. 2019 Jan;80(1):43–53.
  • Reddy SP, Shah VV, Wu JJ. Apremilast for a psoriasis patient with HIV and hepatitis C. J Eur Acad Dermatol Venereol. 2017;31(11):e481–e482.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.